SYNARC to Attend CTAD Conference in 2013

Newark, CA – October 9, 2013 - Synarc, the world's leading provider of medical imaging services for the pharmaceutical, biotechnology, and medical device industries, announced today that their team of Alzheimer's experts will be attending and presenting at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego, CA November 14-16, 2013. Synarc presenters at the conference are Joonmi Oh, Ph.D., David Scott, Ph.D., Gregory Klein, Ph.D., Jerome Barakos, M.D. and Joyce Suhy, Ph.D. Dr. Suhy is also an active member of the E.U./U.S. Task Force on designing drug trials for Alzheimer's Disease.

The Synarc team, together with Synarc's scientific advisor Dr. Michael Weiner, have more experience in conducting trials in Alzheimer's Disease (AD) than any other central imaging provider. Synarc has supported the clinical development of over 65 clinical trials in Alzheimer's Disease and related dementias through management of their MRI and PET biomarkers. These span the full range of eligibility, safety and efficacy assessments including detection of Amyloid Related Imaging Abnormalities (ARIA), brain atrophy with structural MRI, connectivity with functional MRI, amyloid plaque burden and Standardized Uptake Value ratios (SUVr) using florbetapir and flutemetamol PET tracers as well as cerebral metabolic rate of glucose using FDG PET.

"CTAD is an outstanding forum for discussing the latest developments in AD trials," stated Michael Weiner. "Our team at Synarc continues to be at the forefront in the use MRI, PET, and fMRI in Alzheimer's clinical trials, as is demonstrated by our diverse set of presentations at the conference."

Drs. Weiner and Suhy, who founded the Neurology program at Synarc in 2001, will be available to meet throughout the conference. Please contact us to schedule an appointment.

Please join us at CTAD by attending our presentations below:

Performance metrics for two large phase III Alzheimer’s Disease clinical trials; an MRI perspective.
Peethala R, Suhy J, Oh J
Oral presentation: Thursday, November 14, 2013 at 11:15am

Resting-state functional MRI standardization for multi-center clinical trials.
Scott D, Chiao P, Sevigny J, Suhy J
Oral presentation: Friday, November 15th 2013 at 1:45pm
Imputation of amyloid status in a mild AD clinical trial cohort using a structural MRI-based shape variation signature.
Tosun-Turgut D, Yu P., Castelluccio P., Chen Y., Suhy J., Siemers E., Schwarz AJ, Weiner MW.
Oral presentation: Thursday, November 14, 2013 at 2pm

Amyloid PET Screening for Enrollment into AD Clinical Trials: An effective enrichment strategy in a Phase 1b Clinical Trial.
Barakos J, Purcell D, Klein G, Suhy J, Oh J, Chiao P, Sevigny J.
Poster presentation

Amyloid PET screening results by APOE ε4 status from a Phase 1b clinical study 221AD103 in prodromal to mild AD patients.
Poster presentation

About Clinical Trials on Alzheimer’s Disease (CTAD) Conference
The Clinical Trials on Alzheimer’s Disease (CTAD) conference has maintained its unique role in AD research as an intimate professional forum for the world's preeminent clinical researchers to share ideas and foster international collaboration. The 6th annual CTAD conference will relate experiences from international teams covering every stage of clinical trials in AD. From animal models to human trials, CTAD 2013 provides an opportunity to learn about the latest results in drug trials as well as important topics such as internet screening of cognition to recruit for clinical trials, designing drug trials taking into account neuropsychiatric symptoms of AD, Down syndrome and AD as well as ethical issues and methodological considerations.

Alzheimer’s Disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s Disease drugs is becoming essential to face up to this challenge. New pathways have been identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy.
About the Synarc Neurology Team
Michael W. Weiner, M.D., is Synarc's Senior Scientific Advisor in Alzheimer's Disease.

William Jagust, M.D., is Synarc's Scientific Advisor for the use of PET in Alzheimer's Disease.

Joyce Suhy, Ph.D. is a leader in the field of imaging for clinical trials of Alzheimer's Disease and related dementias.

Jerome Barakos, M.D. is a board-certified neuroradiologist who leads Synarc's team on neuroradiological endpoints.

Joonmi Oh, Ph.D. quantitative MRI analysis expert, provides scientific oversight and guidance to Synarc's neurology program.

Gregory Klein, Ph.D., a well-regarded expert in the field of PET imaging, leads Synarc's molecular imaging efforts.

David Scott, Ph.D., functional MRI (fMRI) expert leads Synarc's fMRI offering in multi-site clinical trials.

About SYNARC
Synarc is the world's premier imaging core lab. At our centers in the United States, Europe, and Asia, we provide our clients with the industry's highest quality of service across modalities and therapeutic areas. Through our state-of-the-art, FDA-compliant software systems, our radiologists and experts efficiently perform quantitative and qualitative assessments of images from clinical sites around the world. For more information, please visit www.synarc.com.